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Glycoprotein B of Human Herpesvirus 8 Is a Component of the Virion in a Cleaved Form
Composed of Amino- and Carboxyl-Terminal Fragments
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Human herpesvirus 8 (HHV-8) or Kaposi’s sarcoma-associated herpesvirus (KSHV) is the only known human member of
the Rhadinovirus genus of the gammaherpesvirus subfamily. Antibodies against peptides representing portions of the aminoand carboxyl-termini of HHV-8 gB were produced and used to detect gB expression in Vero cells transfected with the gB
gene, in the HHV-8-harboring cell line, BCBL-1, and in purified virions. Expression of gB was detected in approximately 3%
of uninduced BCBL-1 cells, while up to 30% of the cells expressed gB after 12-O-tetradecanoylphorbol-13-acetate (TPA)
induction of virus replication. Indirect immunofluorescence assays and confocal microscopy showed that gB was distributed
throughout the cytoplasm of BCBL-1 cells and transfected Vero cells. Immunoblot analyses of virion preparations revealed
the presence of full-length as well as two smaller than full-length gB-derived species corresponding to the amino- and
carboxy-terminal portions of gB, respectively. Biochemical analysis of the gB carbohydrate moieties using glycosylation
inhibitors revealed that gB contained N-linked oligosacharides of the high-mannose type, characteristic of precursor
carbohydrate chains added in the endoplasmic reticulum. © 2000 Academic Press

human gamma-2 herpesvirus identified (Moore et al.,
1996).
The present study was carried out to determine
whether gB is a component of the HHV-8 virion and
whether certain biochemical properties of HHV-8 gB are
similar to those reported for other gB homologs. Antibodies against peptides representing portions of the aminoand carboxyl-termini of HHV-8 gB were produced and
used to detect gB expression in Vero cells transfected
with the gB gene, in the HHV-8-harboring lymphoma cell
line, BCBL-1, and in purified virions. We found that gB is
part of the HHV-8 virion as full-length and cleaved protein
and shares biochemical characteristics with other gB
homologs.

INTRODUCTION
Glycoprotein B (gB) is one of the most conserved
herpesvirus glycoproteins. It is an essential virion component for members of the alpha- and betaherpesvirus
subfamilies. It is thought to function in virion attachment
and virus entry into susceptible cells (Cai et al., 1988;
Cranage et al., 1986; Pereira, 1994; Roizman and Sears,
1996; Spear, 1993a). Epstein-Barr virus (EBV), a gamma-1
herpesvirus (genus Lymphocryptovirus) (Honess, 1984),
and murine gammaherpesvirus 68 (MHV-68), which is a
member of the gamma-2 herpesvirus (genus Rhadinovirus) subfamily, do not incorporate detectable levels of gB
into their virions (Gong and Kieff, 1990; Stewart et al.,
1994). However, bovine herpesvirus 4, also a gamma-2
herpesvirus (Bublot et al., 1992; Lomonte et al., 1997),
incorporates gB to its virion (Lomonte et al., 1997).
Human herpesvirus 8 (HHV-8), or Kaposi’s sarcomaassociated herpesvirus, is associated with Kaposi’s sarcoma, primary effusion lymphoma, and multicentric
Castlesman’s disease (Cesarman et al., 1996; Chang et
al., 1994; Said et al., 1996; Soulier et al., 1995). Phylogenetic analyses of viral DNA sequences revealed that
HHV-8 belongs to the gamma-2 sublineage of the gammaherpesvirus subfamily, and thus represents the first

RESULTS
Expression of HHV-8 gB in Vero cells transfected with
the gB gene and in BCBL-1 cells. To facilitate the detection of gB, anti-peptide antibodies were produced
against synthetic peptides representing immunogenic
portions of gB. Peptides were coupled to keyhole limpet
hemocyanin (KLH) before immunization of rabbits (see
Materials and Methods). To validate the specificity of the
rabbit antisera generated against HHV-8 gB peptides,
Vero cells were transfected with the pcDNA-gB plasmid
carrying the entire gB gene under the promoter control of
the human cytomegalovirus immediate early promoter,
and gB expression was detected by IFA at 48 h posttransfection. Antibodies gB-N1 and gB-C detected gB in
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FIG. 1. Immunofluorescence detection of HHV-8 gB using anti-gB-peptide antibodies. Vero cells transfected with the pcDNA-gB plasmid were fixed
with methanol at 48 h after transfection (A, B). Indirect immunofluorescence was performed with the gB-N1 antibody (A, C, E) and with the gB-C
antibody (B, D, F). Uninduced BCBL-1 cells (C, D) and TPA-induced BCBL-1 cells (E, F) reacted with gB-N1 (C, E) or gB-C (D, F) at 2 days after TPA
treatment. Cells were visualized by fluorescence microscopy at 400X magnification.

approximately 5% of the cells, and fluorescent signals
were dispersed throughout their cytoplasm (Fig. 1A, B).
The reactivities of the antibodies were then tested
against BCBL-1 cells. Antibodies gB-N1 and gB-C reacted strongly with approximately 3% of uninduced (Fig.
1C, D) and up to 30% of TPA-induced BCBL-1 cells (Fig.
1E, F). Fluorescent signals were distributed throughout
the cytoplasm and perinuclear spaces. No reactivity was
detected in Vero cells transfected with the plasmid vector alone or with preimmune sera (not shown).
To improve the visualization of gB distribution within
cells, BCBL-1 cells were fixed with paraformaldehyde
and labeled with the gB peptide antibodies as well as
with a nuclear counterstain as described under Materials and Methods and then examined by confocal microscopy (Fig. 2). Although paraformaldehyde is sometimes
used to crosslink the surface of cells to prevent antibody
penetration, induced BCBL-1 cells that had been treated
with paraformaldehyde were permeable to antibodies
directed against nuclear membrane and endoplasmic
reticulum proteins (not shown), thus the reactivity seen

here was not limited to the cell surface. Reactivity with
antibody gB-N1 and gB-N2 was detected in the cytoplasm of TPA-induced BCBL-1 cells (Fig. 2, panels 1 and
2, respectively); however, gB-N1 produced a more intense fluorescent signal than the gB-N2 antibody. Antibody gB-C reacted strongly with paraformaldehyde-fixed
BCBL-1 cells (Fig. 2, panel 3). Antibodies gB-N1 (Fig. 2,
panel 4), gB-N2, and gB-C (not shown) produced very
weak signals against uninduced cells. In addition, confocal microscopy of TPA-induced BCBL-1 cells revealed
cellular structures that contained gB but without any
detectable nuclear material. The largest of these structures was approximately the size of mononuclear
BCBL-1 cells (Fig. 2, panel 1). These structures may
represent cytosolic portions of cells that blebbed off after
TPA induction.
Synthesis and processing of HHV-8 gB in COS cells
transfected with the gB gene and in BCBL-1 cells. COS
cells were transfected with the gB gene and gB was
detected by immunoblot analysis at 48 h posttransfection
in the presence or absence of the N-glycosylation inhib-
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FIG. 2. Confocal immunofluorescence detection of gB in BCBL-1 cells. TPA-induced and uninduced BCBL-1 cells were harvested 5 days after
induction and mounted onto slides after fixing with 3% paraformaldehyde. Indirect immunofluorescence was performed with the indicated antibodies.
Panel 3 shows a representative syncytium structure. Blebbing structures containing gB have no visible nucleus in panel 1.

itor tunicamycin (TM) (Fig. 3). Antibody gB-C reacted with
a 107-kDa protein (Fig. 3A, lane 2). In the presence of TM,
the 107-kDa protein species was not detected, while a
new protein species of approximately 85 kDa appeared
(Fig. 3A, lane 3). For comparison, antibody gB-C reacted
against extracts from purified HHV-8 virions detected
112-, 107-, and 59-kDa proteins (Fig. 3, lane 4).
Similar experiments were performed to detect gB in
uninduced and TPA-induced BCBL-1 cells in the presence and absence of glycosylation inhibitors (Fig. 3B).
Antibody gB-C reacted with major protein species of
112-, 107-, and 59-kDa in TPA-induced cells (Fig. 3B, lane
2). Proteins of similar sizes were present in substantially
lower amounts in uninduced cells (Fig. 3B, lane 1). The
relative amounts of other protein species did not change
after TPA induction and thus were considered to represent background reactivity (Fig. 3B, lanes 1 and 2). To
inhibit N-linked glycosylation, TM was added to BCBL-1
cells concurrent with TPA induction, and cells were harvested 2 days later. The amounts of the 112-, 107-, and
59-kDa proteins were drastically reduced in the presence of TM, while a new gB-C-reactive species of approximately 90 kDa was detected (Fig. 3B, lane 3). The
processing pathway of gB in induced BCBL-1 cells was
further examined using endoglycosidase H (endo-H),
which specifically cleaves high mannose, non-Golgi pro-

cessed sugars (Tarentino et al., 1989; Maley et al., 1989).
Digestion by endo-H of extracts from cells induced by
TPA in the absence of TM produced gB species ranging
in molecular mass from 112–90 to 51–46 kDa (Fig. 3B,
lane 4 compared to lane 2). Peptide N-glycosidase F
(PNGase F) is an amidase that cleaves between the
innermost GlcNAc and asparagine residues of high mannose, hybrid, and complex oligosacharides from N-linked
glycoproteins (Maley et al., 1989; Tarentino et al., 1990).
Digestion with PNGase F of extracts of BCBL-1 cells
induced by TPA in the absence of TM produced two
major gB-C-reactive species of approximately 98–90 and
46 kDa (Fig. 3B, lane 5).
Detection of gB and gB-related peptides in HHV-8
virions. The gB-C and gB-N1 antibodies were used to
detect gB in purified virion samples obtained from supernatant fluids by differential centrifugation or by purifying virions through density gradients (see Materials
and Methods). Antibody gB-C reacted specifically with
the proteins of 112-, 107-, and 59-kDa apparent molecular
masses in immunoblots of electrophoretically separated
proteins from purified virions obtained from supernatants
(Fig. 3A, lane 4; Fig. 3B lane 6; Fig. 4A, lane 1) as well as
from gradient-purified virions (Fig. 4A, lane 2). The
amounts of the 112- and 107-kDa proteins were decreased in gradient-purified virion samples in compari-
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FIG. 3. The effect of glycosylation inhibitors on gB expressed in COS
and BCBL-1 cells. (A) COS cells were transfected with the HHV-8 gB
gene-expressing plasmid and incubated in the presence or absence of
TM. Cellular extracts were collected at 48 h posttransfection and tested
for the presence of gB in immunoblots using the gB-C antibody. Lane 1:
mock-transfected COS cells. Lanes 2 and 3: COS cells transfected with
the gB gene in the absence and presence of TM, respectively. Lane 4:
extracts of virions purified from BCBL-1 supernates. The location of the
107-kDa gB species in lane 2 and the location of the gB-doublet of 112and 107-kDa species in lane 4 are marked with a solid dot. The location
of the 85-kDa species produced in the presence of TM is marked by an
arrow in lane 3. (B) BCBL-1 cells incubated in the presence of TPA
alone or in the presence of TPA and TM were harvested at 48 h
post-TPA induction. Cellular extracts derived from TPA-induced BCBL-1
cells were treated with either endo-H or PNGase F. Immunoblot analysis was used to detect gB using antibody gB-C. Lane 1: BCBL-1 cells
in the absence of TPA induction. Lane 2: BCBL-1 cellular extracts after
TPA induction. Lane 3: BCBL-1 cellular extracts after TPA and TM
treatment. Lane 4: sample from TPA-induced cells digested with
endo-H. Lane 5: TPA-induced cellular extracts digested with PNGase F.
Lane 6: virion extracts reacted with anti-gB-C antibody. The location of
the 112-kDa species in lane 6 is marked with a solid dot. The location
of the 59-kDa species in lane 6 is marked with a solid square. The
location of the 90-kDa species produced in the presence of TM is
marked by an arrow in lane 3.

son to the purified virion samples obtained from supernatant fluids, while a smaller protein of approximately
40-kDa apparent molecular mass was present in virions
obtained from supernatant fluids but not present in density gradient-purified virion samples (Fig. 4A, lanes 1 and
2). Antibody gB-N1, which reacts with the amino-terminal
portion of gB, detected specifically a 75-kDa protein
species in virion samples purified from either supernatant fluids or through density gradients. Decreased
amounts of the 75-kDa protein were detected in gradientpurified samples in comparison to virion samples obtained from supernatant fluids (Fig. 4B, lanes 1 and 2,
respectively).
The processing pathway of gB in purified virions was
further examined using enzymes endo-H and endo-F.
Antibody gB-C reacted specifically with proteins of 112–
107 and 59 kDa (apparent molecular masses) in immunoblots of electrophoretically separated proteins from
purified virions (Fig. 5, lane 4), which exhibited similar
mobilities to gB-C antibody-reactive protein species from
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TPA-induced BCBL-1 cells that served as controls (Fig. 5,
lane 3). For comparative purposes, the gB-C antibody
was also reacted against extracts from both BJAB cells
as well as BCBL-1 cells in the absence of TPA induction.
The gB-C antibody did not react with proteins of 112–107
kDa; however, it did react with a protein species of
approximately 57 kDa that was present in samples from
both BJAB and uninduced BCBL-1 cells (Fig. 5, lanes 1, 2).
The fact that the 57-kDa protein was detected in both
BJAB and BCBL-1 cells without TPA induction indicates
that this reaction was nonspecific. Digestion by endo-H
of extracts from purified virions produced gB species
with faster electrophoretic mobilities ranging in apparent
molecular mass of approximately 107–90 and 51–45 kDa
(Fig. 5, lane 5 compared to lane 4). Digestion of purified
virions with PNGase F produced two major gB-C-reactive
species of approximately 95–90 and 45 kDa (Fig. 5, lane
6).
DISCUSSION
We produced specific antibodies against HHV-8 gB
and demonstrated that unlike EBV gB, HHV-8 gB is a
major component of the virion particle. Furthermore, we
demonstrated that gB is incorporated in virions as fulllength and cleaved forms and that it is predominantly
N-glycosylated.
gB homologs specified by varicella zoster virus (VZV),

FIG. 4. Detection of gB in purified virions. Virions were purified from
the supernatant fluids of BCBL-1 cells prepared 2 days after TPA
addition. Purified viral antigens were reacted in immunoblots with gB-C
and gB-N1 antibodies and visualized using chemiluminescence. (A)
Lanes 1 and 2: extracts of virions purified from either supernatant fluids
or density gradients, respectively, reacted with the gB-C antibody. The
location of the 112-kDa gB species is marked with a solid dot and the
59-kDa gB species is marked with an asterisk. (B) Lanes 1 and 2:
extracts of virions purified from either supernatant fluids or density
gradients, respectively, reacted with the gB-N1 antibody. The location of
the 75-kDa gB species in B is marked with an arrowhead. Molecular
mass markers are as shown and are the same for both A and B.
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FIG. 5. The effect of glycosylation inhibitors on gB expressed in
purified virions. (A) Immunoblot analysis was used to detect gB in
samples prepared from cellular extracts and virions purified from supernatant fluids of BCBL-1 cells using antibody gB-C. In addition,
purified virion samples were digested with either endo-H or PNGase F.
Cellular extracts obtained from either BJAB or BCBL-1 cells without TPA
induction were reacted with the gB-C antibody and served as background controls. Lane 1: BJAB cells. Lane 2: BCBL-1 cells in the
absence of TPA induction. Lane 3: BCBL-1 cellular extracts after TPA
induction. Lane 4: purified virion samples in the absence of any enzymatic treatment. Lane 5: purified virions digested with endo-H. Lane 6:
purified virion samples digested with PNGase F. The location of the
112-kDa species in lane 6 is marked with a solid dot. The location of the
59-kDa species in lane 6 is marked with a star. The locations of the
45-kDa gB species produced after either endo-H or PNGase F treatment is marked with an arrowhead, while the 90-kDa gB species is
marked with an asterisk.

human cytomegalovirus, human herpesvirus 6, bovine
herpesvirus 1 (BHV-1), bovine herpesvirus 4 (BHV-4),
pseudorabies virus, Marek’s disease virus, equine herpesvirus 1, equine herpesvirus 4 (EHV-4), murine cytomegalovirus, and feline herpesvirus 1 are proteolytically
cleaved into two major parts after digestion between the
R and S amino acids of the consensus site RX(R/K)RS
which is located near the middle of the extracellular
domain of the molecule (Pereira, 1994). The cleaved
domains retain their covalent association via disulfide
bonds (Pereira, 1994; Spaete et al., 1988). However,
cleavage of the BHV-1 gB molecule was shown not to be
required for gB function (Kopp et al., 1994). The predicted
primary sequence of HHV-8 gB includes a potential proteolytic cleavage site (RKRR/S) located between amino
acids 440 and 441 of the HHV-8 gB predicted amino acid
sequence. The predicted molecular weight of the amino
acid backbone of HHV-8 gB is 93,978 and 91,307 Da
without its predicted signal sequence (aa 1–26). The
predicted molecular weights of the amino and carboxyl

terminal portions obtained after proteolytic cleavage are
45,879 and 45,445 Da, respectively, which correspond to
the probable peptide backbones of the 75- and 59-kDa
N-terminal and C-terminal gB species detected in cells
and virions.
Glycosylation inhibition experiments revealed that
HHV-8 gB contains predominantly N-linked carbohydrates in agreement with a previous report describing
the gB specified by the closely related BHV-4 (Lomonte
et al., 1997) as well as with HHV-8 gB transiently expressed in Chinese hamster ovary (CHO) cells (Pertel et
al., 1998). The amino-terminal portion of HHV-8 gB contains 9 potential N-linked glycosylation sites, while the
carboxy-terminal portion contains 6 sites. Therefore, the
59-kDa species detected in immunoblots of antigens
derived from both BCBL-1 cells and purified virions with
the gB-C antibody may be obtained by glycosylation of
the 45-kDa carboxyl-terminal portion of gB. The 75-kDa
species detected in purified virions with the gB-N1 antibody most likely represents the glycosylated version of
the 46-kDa amino terminal portion of gB. The 112-, 107-,
and 59-kDa gB species contain N-linked sugars because
their apparent molecular masses were reduced after
endo-H treatment. This conclusion was confirmed by the
TM experiments with BCBL-1 cells in which the 112- and
107-kDa gB species were replaced by a species of 90
kDa. In these experiments, the amount of 59-kDa protein
was reduced drastically in the TM-treated sample, indicating that the potential precursor protein of the 59-kDa
protein may be rapidly degraded in the absence of Nglycosylation.
In contrast to results obtained by transiently expressing gB in CHO cells where it was found that gB was
localized in the rough endoplasmic reticulum (RER) and
perinuclear spaces (Pertel et al., 1998), gB expressed in
BCBL-1 cells as well as in Vero cells was distributed
throughout the cytoplasm. These differences in gB distribution detected by immunofluorescence assays may
be due to the different cell lines used in these studies,
the relative amounts of gB expressed under different
conditions, or the different antibodies used to detect gB.
In the presence of TM, a 85-kDa protein was detected
in COS cells transfected with the gB gene instead of the
90-kDa gB expressed in the presence of TM in BCBL-1
cells indicating that the nonglycosylated gB precursor
protein may be partially digested in COS cells. Similar
transient expression experiments in CHO cells indicated
that the full-length gB migrated with an apparent molecular mass of approximately 120 kDa, while gB in the
presence of TM was approximately 95 kDa (Pertel et al.,
1998). The discrepancies in molecular masses between
COS, CHO, and BCBL-1 cells for gB and gB-related peptides may be due to differences in the extent of gB
glycosylation by the different cells used in these studies.
It is important to note that under transient expression
conditions, gB is expressed as full-length, while in
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BCBL-1 cells is produced as amino- and carboxyl-terminal portions as well as full-length gB. Thus, it seems that
there is a protease that is responsible for cleavage of gB
in BCBL-1 cells.
Apparently, gB exists in virions as a full-length protein
as well as in a cleaved form consisting of a 75-kDa
amino terminal portion and a 59-kDa carboxyl-terminal
portion. Addition of the apparent molecular masses of
these two gB species should produce a full-length gB of
approximately 134 kDa instead of the 112-kDa gB detected by gB-C and gB-N1 antibodies. This discrepancy
between predicted and observed molecular masses for
full-length gB may be due to slower electrophoretic migration of gB fragments in comparison to the full-length
gB. Double-gradient virions appeared to have less fulllength gB than virions produced from BCBL-1 supernates. We considered that this difference between the
two virion preparations may be due to either contaminating full-length gB in BCBL-1 supernates or partial processing of gB after virion purification. However, doublegradient purification should eliminate any specific proteases, and therefore, it is unlikely that specific cleavage
of gB could be achieved after virus purification. Therefore, our results are consistent with the hypothesis that
gB is found in HHV-8 virions predominantly as 75- and
59-kDa fragments. Furthermore, the amino-terminal portion of gB does not contain any predicted membrane
spanning amino acid sequences; therefore it is likely to
be retained on virions through association with the gBcarboxyl-terminal portion.
Addition of protease inhibitors such as phenylmethylsulfone fluoride (PMSF) or a mixture of N-tosyl-L-phenylananine chloromethyl ketone (TPCK) and N-p-tosyl-Llysine chloromethyl ketone (TLCK) protease inhibitors
prior and during cellular disruption failed to inhibit proteolytic cleavage of gB, indicating that this activity does
not occur after lysis due to lysosomal enzymes that are
released by cellular disruption (not shown). Transient
expression of gB in COS cells revealed the presence of
full-length gB, while the 59-kDa portion of gB detected in
BCBL-1 cells was not detected (Fig. 3A). Similar results
were obtained in experiments in which gB was expressed in BHK-1 cells under transient conditions using
plasmid-based expression vectors or the Semliki Forest
Virus expression System (DiCiommo and Bremner, 1998).
Moreover, extracts prepared from uninduced BCBL-1 or
BJAB cells, when incubated with gB expressed via transient expression in COS cells, failed to cleave gB and
produce the 59-kDa gB species (not shown). Thus, gB
cleavage seems to be intimately associated with gB
expression in BCBL-1 cells.
Amino acid sequences of gB are highly conserved
among herpesviruses. Furthermore, gB specified by alpha- and betaherpesviruses function in virus entry and
virus-induced cell fusion (Pereira, 1994; Spear, 1993a,b).
Apparently, these membrane fusion functions of gB are
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not shared by the EBV gB homolog, because EBV gB is
not found in EBV virions and is not expressed on the
surface of infected cells, but it is strictly localized on the
rough endoplasmic reticulum and nuclear membranes
(Emini et al., 1987; Gong et al., 1987; Gong and Kieff,
1990; Qualtiere and Pearson, 1979). In contrast, both
BHV-4 (Lomonte et al., 1997) and HHV-8 contain gB in
their virions, and HHV-8 expresses gB throughout the
cytoplasm of BCBL-1 cells. The presence of gB in HHV-8
virions suggests that it may function in virion entry.
MATERIALS AND METHODS
Cells and virus purification. BJAB cells were obtained
from Naoki Inoye (Centers for Disease Control and Prevention, Atlanta, GA). BCBL-1 cells (Renne et al., 1996)
were obtained from the NIH AIDS Reference and Reagent Program and cultured according to the instructions
provided. The lytic cycle was induced by treatment with
20 ng/ml of the phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (Sigma Chemical Corp., St. Louis, MO).
Vero cells were grown in Dulbecco’s modification of
Eagle’s medium supplemented with 7% heat-inactivated
fetal calf serum and penicillin and streptomycin. For virus
purifications, 5 liters of induced BCBL-1 cell supernatants was harvested at 8 days postinduction (d.p.i.) and
filtered through a 0.45-m filter and then virions were
pelleted at 22,000 g for 16 h. Virion pellets were allowed
to resuspend overnight on ice in TNE buffer (0.1 M Tris,
pH 7.4, 0.1 M NaCl, 0.001 M EDTA) containing protease
inhibitors. Pellets were pooled and layered onto a 20–
35% Accudenz (Accurate Chemical Corp., Westbury, NY)
step gradient and then centrifuged at 82,500 g in a
swinging bucket rotor for 2 h at 5°C. The band visible at
the interface was collected, diluted with cold TNE,
layered onto a 15–50% continuous Accudenz gradient,
and centrifuged as described above. A single-wide band
of 1.5 ml was collected, diluted with TNE, layered onto a
second 15–50% continuous Accudenz gradient, and centrifuged under identical conditions. The final band was
collected and diluted in 10 ml of Tris-buffered saline
(TBS), and then virions were pelleted at 77,000 g in a
swinging bucket rotor for 1 h at 5°C. Electron microscopic examination of purified virions revealed a high
concentration of apparently intact virions and very little
visible cellular debris.
Alternatively, viruses were partially purified by separately harvesting cells and supernatants obtained from
two 250-ml cell cultures. Supernatant fluids were centrifuged at 1500 g to remove any cells and kept in ice. Cells
were collected by centrifugation, suspended into 10 ml of
PBS buffer, freeze-thawed three times, and subsequently
centrifuged at 1500 g in a preparative centrifuge for 15
min. Supernates from these preparations were combined
with clarified supernates from the original cell cultures.
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These fluids were cleared by centrifugation at 5000 g for
30 min and passed through a 0.2-m filter. Filtered virions were pelleted at 27,000 g for 3 h and then viral
pellets were resuspended in 40 ml of phosphate-buffered saline (PBS) and repelleted as above. Pellets were
resuspended in 200–300 l of PBS before processing for
SDS-PAGE. Electron microscopic examination showed
that these preparations contained high concentrations of
virions and low amounts of cellular debris (not shown).
Plasmid construction (pcDNA-gB). HHV-8 glycoprotein
B was amplified by PCR from BCBL-1 cells with primers
5⬘-GGAATTCCGCTAGCTGGGTATTTAAGGACCTGTAC
and 5⬘-CGGGATCCAAGCTTAGAGGCGGGCCGT GTTTCCTA based on the BCBL-1 gB DNA sequence (Meng et
al., in press). The resulting PCR product, which contains
59 bp of the 5⬘ nontranslated sequence, the entire openreading frame, and the stop codon, was cloned into
pcDNA 3.1/Zeo (⫹) (Invitrogen, Inc., Carlsbad, CA) using
the unique restriction sites NheI and BamHI, yielding the
recombinant plasmid pcDNA-gB. The ends of the cloned
gB DNA fragment were sequenced using the T7-forward
and pcDNA3.1/BGH-reverse primers (Invitrogen, Inc.) to
confirm that gB was correctly inserted for expression.
CsCl 2-purified plasmid DNA was used for transient expression experiments.
Peptide synthesis and immunizations. Peptides representing three regions of the predicted translation product
of the HHV-8 gB gene were synthesized using an automated peptide synthesizer (Model 432A, Applied Biosystems, Foster City, CA) according to the manufacturers
instructions. Peptide gB2575 (gB-N1) contained aa 27–
42, peptide gB2518 (gB-N2) contained aa 167 to 191, and
peptide gB2523 (gB-C) contained aa 828 to 845. Synthetic peptides were coupled to keyhole limpet hemocyanin, emulsified with Freund’s complete adjuvant for the
primary immunization and Freund’s incomplete adjuvant
for two booster immunizations. Two New Zealand white
rabbits per peptide were immunized subcutaneously
with each conjugated peptide.
Transfection and immunofluorescence assays. Vero
cells were seeded in 24-well plates on glass coverslips.
When cells reached 50–60% confluency, they were transfected with the plasmid pcDNA-gB using Lipofectamine
reagent according to the manufacturer’s instructions
(Life Technologies, Gaithersburg, MD). Transfected cells
were incubated for 48 h at 37°C, and then coverslips
were fixed with methanol for 20 min, rinsed three times
with PBS, and then processed for immunofluorescence
staining. Rabbit antisera to gB peptides (see below) were
used in IFA at a dilution of 1:100 in 10% normal goat
serum in PBS. BCBL-1 cells were centrifuged onto a slide
using a cytospin centrifuge and processed as detailed
above for the gB gene-transfected Vero cells. Fluorescein-conjugated goat anti-rabbit antibody (ICN Pharmaceuticals, Inc., Aurora, OH) was used as the secondary
antibody.

Confocal microscopy. Cytospin-prepared cells were
fixed in paraformaldehyde (3% in PBS) and then incubated with the indicated antiserum for 1 h at 4°C followed by washing three times with ice-cold PBS. Incubation with the secondary antibody, Oregon Green 488conjugated goat anti-rabbit IgG (Molecular Probes, Inc.,
Eugene, OR) at a 1:200 dilution in 20% horse serum in
PBS) was used at 4°C for 1 h. Microscopic examination
was with a Zeiss LSM 410 inverted confocal microscope
equipped with an argon/krypton laser and a 40X (1.2
N.A.) objective using the appropriate excitation and
emission filters.
Immunoblot analysis. Cell lysates or purified virions
were diluted in loading buffer (2% SDS, 1% 2-mercaptoethanol, 10% glycerol, and 0.001% bromphenol blue in
0.5 M Tris-HCl, pH 6.8) and separated by SDS-PAGE
(Laemmli, 1970) in 10% polyacrylamide gels. Proteins
were electrotransferred onto nitrocellulose membranes,
blocked with BLOTTO (5% nonfat milk in 0.01 M PBS/
0.05% Tween 20), and then reacted 1 h with the indicated
gB peptide antiserum at a dilution of 1:400 at room
temperature. Membranes were washed three times with
the same buffer and proteins were visualized by either
alkaline phosphatase or chemiluminescence (Alkaline
Phosphatase Conjugate Substrate Kit, Bio-Rad, Inc., Hercules, CA; SuperSignal Substrate Western blotting
chemiluminescence detection kit, Pierce, Inc., Rockford,
IL).
Glycosylation studies. Tunicamycin was purchased
from Boehringer Mannheim Corp. (Indianapolis, IN). Endoglycosidase H and peptide endoglycosidase F (PNGase F) were purchased from New England BioLabs
(Beverly, MA). Approximately, 10 6 BCBL-1 cells were obtained from cell cultures grown in the presence or absence of TPA for 48 h. Other BCBL-1 cell cultures were
incubated in the presence of TM (1 g/ml) added simultaneously with TPA. Cells were collected by low-speed
centrifugation (5 min at 500 g), washed by resuspending
and pelleting in PBS, and then lysed in 750 l of doubledistilled water. Cellular extracts were sonicated for 7 s
(Sonifier Cell Disruptor 200, Branson, Inc., Danbury, CT)
and centrifuged (5 min at 1000 g), and then supernatants
were collected. Endo-H and PNGase-F digestions were
performed on 100 l of cellular extracts using 1000 U of
each enzyme per reaction for 1 h at 37°C, and otherwise
according to the manufacturer’s instructions (New England BioLabs). Enzyme reactions were stopped by the
addition of loading buffer to samples for SDS-PAGE analysis.
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